In our patient cohort we noticed that levels of several cytokines and chemokines (IL-6, IL-12, IP-10, eotaxin, MCP-1, and IFN-γ) were increased in CML patients treated with IFN-α. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.